T1	CHEM 104 115	rivaroxaban
#1	AnnotatorNotes T1	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T2	CHEM 121 144	ácido acetil salicílico
#2	AnnotatorNotes T2	C0004057; aspirin; Organic Chemical · Pharmacologic Substance
T3	CHEM 164 175	clopidogrel
#3	AnnotatorNotes T3	C0070166; clopidogrel; Organic Chemical · Pharmacologic Substance
T4	CHEM 178 188	ticagrelor
#4	AnnotatorNotes T4	C1999375; ticagrelor; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T5	DISO 206 230	síndrome coronario agudo
#5	AnnotatorNotes T5	C0948089; Acute Coronary Syndrome; Disease or Syndrome
T6	PROC 253 381	Estudio multicéntrico, aleatorizado, doble ciego, doblemente enmascarado, controlado con tratamiento activo, de grupos paralelos
T7	PROC 387 408	comparar la seguridad
T8	DISO 636 639	SCA
T9	CHEM 412 423	Rivaroxabán
#6	AnnotatorNotes T9	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T10	CHEM 434 456	Ácido Acetilsalicílico
#7	AnnotatorNotes T10	C0004057; aspirin; Organic Chemical · Pharmacologic Substance
T11	CHEM 476 487	Clopidogrel
#8	AnnotatorNotes T11	C0070166; clopidogrel; Organic Chemical · Pharmacologic Substance
T12	CHEM 490 500	Ticagrelor
#9	AnnotatorNotes T12	C1999375; ticagrelor; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T13	DISO 518 542	Síndrome Coronario Agudo
#10	AnnotatorNotes T13	C0948089; Acute Coronary Syndrome; Disease or Syndrome
T14	DISO 566 583	Ataque al corazón
#11	AnnotatorNotes T14	C0027051; Myocardial infarction; Disease or Syndrome | C0155626; Acute myocardial infarction; Disease or Syndrome
T15	DISO 610 634	Síndrome Coronario Agudo
#12	AnnotatorNotes T15	C0948089; Acute Coronary Syndrome; Disease or Syndrome
T16	DISO 718 726	síntomas
#13	AnnotatorNotes T16	C1457887; Symptoms; Sign or Symptom
T17	DISO 743 767	síndrome coronario agudo
#14	AnnotatorNotes T17	C0948089; Acute Coronary Syndrome; Disease or Syndrome
T18	DISO 775 781	angina
#15	AnnotatorNotes T18	C0002962; Angina Pectoris; Sign or Symptom
T19	DISO 784 792	síntomas
#16	AnnotatorNotes T19	C1457887; Symptoms; Sign or Symptom
T20	PROC 852 872	ingreso hospitalario
#17	AnnotatorNotes T20	C0184666; Hospital admission; Health Care Activity
T21	PROC 915 928	hospitalizado
#18	AnnotatorNotes T21	C0019993; Hospitalization; Health Care Activity
T22	PROC 941 952	diagnóstico
#19	AnnotatorNotes T22	C0011900; Diagnosis; Diagnostic Procedure
T23	DISO 960 1010	Infarto de miocardio con elevación del segmento ST
T24	DISO 1012 1017	STEMI
#20	AnnotatorNotes T24	C1536220; ST segment elevation myocardial infarction; Disease or Syndrome
T25	DISO 1024 1078	síndrome coronario agudo sin elevación del segmento ST
#21	AnnotatorNotes T25	C3160886; Non ST segment elevation acute coronary syndrome; Disease or Syndrome
T26	DISO 895 898	SCA
T27	DISO 1167 1184	diabetes mellitus
#22	AnnotatorNotes T27	C0011849; Diabetes Mellitus; Disease or Syndrome | C1802373; Diabetes mellitus (incl subtypes); Disease or Syndrome
T28	DISO 1209 1229	infarto de miocardio
#23	AnnotatorNotes T28	C0027051; Myocardial infarction; Disease or Syndrome | C0155626; Acute myocardial infarction; Disease or Syndrome
T29	DISO 1258 1261	SCA
T30	PROC 1459 1470	tratamiento
#24	AnnotatorNotes T30	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T31	CHEM 1508 1522	anticoagulante
#25	AnnotatorNotes T31	C0003280; Anticoagulants; Pharmacologic Substance
T32	CHEM 1525 1550	antiagregante plaquetario
#26	AnnotatorNotes T32	C0085826; Antiplatelet Agents; Pharmacologic Substance
T33	PROC 1583 1628	terapia de mantenimiento antiplaquetario dual
T34	DISO 1492 1495	SCA
T35	CHEM 1648 1659	clopidogrel
#27	AnnotatorNotes T35	C0070166; clopidogrel; Organic Chemical · Pharmacologic Substance
T36	CHEM 1662 1685	Ácido Acetil Salicílico
#28	AnnotatorNotes T36	C0004057; aspirin; Organic Chemical · Pharmacologic Substance
T37	CHEM 1692 1702	Ticagrelor
#29	AnnotatorNotes T37	C1999375; ticagrelor; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T38	CHEM 1705 1728	Ácido Acetil Salicílico
#30	AnnotatorNotes T38	C0004057; aspirin; Organic Chemical · Pharmacologic Substance
T39	PROC 1750 1774	continuar el tratamiento
#31	AnnotatorNotes T39	C2091305; continue current medication; Therapeutic or Preventive Procedure
T40	ANAT 1953 2005	muestra farmacogenómica de ácido desoxirribonucleico
#32	AnnotatorNotes T40	C0444245; Deoxyribonucleic acid sample; Cell component
T41	DISO 2612 2624	intolerancia
#33	AnnotatorNotes T41	C0277585; Intolerance to drug; Pathologic Function
T42	CHEM 1849 1868	inhibidor del P2Y12
T43	PROC 1884 1898	aleatorización
#34	AnnotatorNotes T43	C0034656; Randomization; Research Activity
T44	CHEM 1980 2005	ácido desoxirribonucleico
#35	AnnotatorNotes T44	C0012854; DNA; Biologically Active Substance · Nucleic Acid, Nucleoside, or Nucleotide
T45	CHEM 2007 2010	ADN
#36	AnnotatorNotes T45	C0012854; DNA; Biologically Active Substance · Nucleic Acid, Nucleoside, or Nucleotide
T46	PROC 2155 2177	terapia anticoagulante
#37	AnnotatorNotes T46	C0150457; Anticoagulant therapy; Therapeutic or Preventive Procedure
T47	DISO 2231 2236	ictus
#38	AnnotatorNotes T47	C0038454; Cerebrovascular accident; Disease or Syndrome
T48	DISO 2269 2297	ataque isquémico transitorio
#39	AnnotatorNotes T48	C0007787; Transient Ischemic Attack; Disease or Syndrome
T49	DISO 2299 2302	TIA
#40	AnnotatorNotes T49	C0007787; Transient Ischemic Attack; Disease or Syndrome
T50	PROC 2340 2360	terapia trombolítica
T51	PROC 2366 2377	tratamiento
#41	AnnotatorNotes T51	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T52	CHEM 2428 2438	ticagrelor
#42	AnnotatorNotes T52	C1999375; ticagrelor; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T53	CHEM 2496 2505	omeprazol
#43	AnnotatorNotes T53	C0028978; omeprazole; Organic Chemical · Pharmacologic Substance
T54	CHEM 2508 2519	esomeprazol
#44	AnnotatorNotes T54	C0937846; esomeprazole; Organic Chemical · Pharmacologic Substance
T55	CHEM 2525 2535	medicación
#45	AnnotatorNotes T55	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T56	CHEM 2552 2563	clopidogrel
#46	AnnotatorNotes T56	C0070166; clopidogrel; Organic Chemical · Pharmacologic Substance
T57	DISO 2593 2600	alergia
#47	AnnotatorNotes T57	C1527304; Allergic Reaction; Pathologic Function
T58	CHEM 2627 2630	AAS
#48	AnnotatorNotes T58	C0004057; aspirin; Organic Chemical · Pharmacologic Substance
T59	ANAT 215 224	coronario
#49	AnnotatorNotes T59	C0205042; Coronary artery; Body Part, Organ, or Organ Component | C1269008; Entire coronary artery; Body Part, Organ, or Organ Component
T60	ANAT 527 536	Coronario
#50	AnnotatorNotes T60	C0205042; Coronary artery; Body Part, Organ, or Organ Component | C1269008; Entire coronary artery; Body Part, Organ, or Organ Component
T61	ANAT 576 583	corazón
#51	AnnotatorNotes T61	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T62	ANAT 619 628	Coronario
#52	AnnotatorNotes T62	C0205042; Coronary artery; Body Part, Organ, or Organ Component | C1269008; Entire coronary artery; Body Part, Organ, or Organ Component
T63	ANAT 752 761	coronario
#53	AnnotatorNotes T63	C0205042; Coronary artery; Body Part, Organ, or Organ Component | C1269008; Entire coronary artery; Body Part, Organ, or Organ Component
T64	ANAT 971 980	miocardio
#54	AnnotatorNotes T64	C0027061; Myocardium; Tissue | C1284309; Entire myocardium; Tissue
T65	ANAT 1033 1042	coronario
#55	AnnotatorNotes T65	C0205042; Coronary artery; Body Part, Organ, or Organ Component | C1269008; Entire coronary artery; Body Part, Organ, or Organ Component
T66	DISO 769 772	SCA
T67	ANAT 1220 1229	miocardio
#56	AnnotatorNotes T67	C0027061; Myocardium; Tissue | C1284309; Entire myocardium; Tissue
T68	DISO 1417 1420	SCA
T69	ANAT 1539 1550	plaquetario
#57	AnnotatorNotes T69	C0005821; Blood Platelets; Cell
T70	CHEM 1608 1623	antiplaquetario
#58	AnnotatorNotes T70	C0085826; Antiplatelet Agents; Pharmacologic Substance
T71	CHEM 1782 1847	antagonista del receptor plaquetario P2Y12 de adenosina difosfato
T72	PROC 1630 1634	DAPT
T73	DISO 1080 1088	NSTE-ACS
#59	AnnotatorNotes T73	C3160886; Non ST segment elevation acute coronary syndrome; Disease or Syndrome
T74	CHEM 2163 2177	anticoagulante
#60	AnnotatorNotes T74	C0003280; Anticoagulants; Pharmacologic Substance
T75	CHEM 2348 2360	trombolítica
#61	AnnotatorNotes T75	C0016018; Fibrinolytic Agents; Pharmacologic Substance
T76	PROC 2470 2484	administración
#62	AnnotatorNotes T76	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T77	CHEM 2633 2644	rivaroxaban
#63	AnnotatorNotes T77	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T78	DISO 2386 2389	SCA
T79	PROC 1291 1303	aleatorizado
#64	AnnotatorNotes T79	C0034656; Randomization; Research Activity
T80	Date 13 17	2014
T81	LIVB 192 201	pacientes
#65	AnnotatorNotes T81	C0030705; Patients; Patient or Disabled Group
T82	LIVB 504 513	pacientes
#66	AnnotatorNotes T82	C0030705; Patients; Patient or Disabled Group
T83	Age 691 704	18 años o más
T84	Duration 830 837	las 48h
T86	Age 1125 1148	54 años de edad o menos
T87	Duration 1356 1370	máximo 10 días
T88	Route 1551 1562	intravenoso
#67	AnnotatorNotes T88	C1522726; Intravenous Route of Drug Administration; Functional Concept
T89	LIVB 2098 2110	investigador
#68	AnnotatorNotes T89	C0035173; Research Personnel; Professional or Occupational Group
T91	Duration 2286 2297	transitorio
#69	AnnotatorNotes T91	C0205374; Transitory; Temporal Concept
T93	Duration 2485 2492	crónica
#70	AnnotatorNotes T93	C0205191; chronic; Temporal Concept
T94	LIVB 673 686	participantes
#71	AnnotatorNotes T94	C4554048; Study Participant; Population Group
T95	LIVB 1108 1121	participantes
#72	AnnotatorNotes T95	C4554048; Study Participant; Population Group
T96	LIVB 1269 1281	participante
#73	AnnotatorNotes T96	C4554048; Study Participant; Population Group
T97	LIVB 1426 1438	participante
#74	AnnotatorNotes T97	C4554048; Study Participant; Population Group
T98	LIVB 1907 1920	participantes
#75	AnnotatorNotes T98	C4554048; Study Participant; Population Group
T99	LIVB 2040 2053	Participantes
#76	AnnotatorNotes T99	C4554048; Study Participant; Population Group
T100	LIVB 2213 2226	Participantes
#77	AnnotatorNotes T100	C4554048; Study Participant; Population Group
T101	LIVB 2445 2457	participante
#78	AnnotatorNotes T101	C4554048; Study Participant; Population Group
T102	LIVB 2307 2320	Participantes
#79	AnnotatorNotes T102	C4554048; Study Participant; Population Group
T103	LIVB 2570 2582	participante
#80	AnnotatorNotes T103	C4554048; Study Participant; Population Group
T104	Spec_cue 731 739	sugieran
T85	PROC 1386 1409	admitido en el hospital
#81	AnnotatorNotes T85	C0184666; Hospital admission; Health Care Activity
A1	Assertion T17 Speculated
A2	Assertion T66 Speculated
A3	Status T28 History_of
A4	Status T30 History_of
A5	Status T31 History_of
A6	Status T32 History_of
A7	Assertion T46 Contraindicated
A8	Assertion T74 Contraindicated
A9	Status T47 History_of
A10	Status T48 History_of
A11	Status T49 History_of
A12	Status T50 History_of
A13	Status T51 History_of
A14	Status T41 History_of
A15	Status T57 History_of
#82	AnnotatorNotes T7	C1705187; Safety Study; Research Activity
#83	AnnotatorNotes T8	C0948089; Acute Coronary Syndrome; Disease or Syndrome
#84	AnnotatorNotes T66	C0948089; Acute Coronary Syndrome; Disease or Syndrome
#85	AnnotatorNotes T26	C0948089; Acute Coronary Syndrome; Disease or Syndrome
#86	AnnotatorNotes T23	C1536220; ST segment elevation myocardial infarction; Disease or Syndrome
#87	AnnotatorNotes T29	C0948089; Acute Coronary Syndrome; Disease or Syndrome
#88	AnnotatorNotes T68	C0948089; Acute Coronary Syndrome; Disease or Syndrome
#89	AnnotatorNotes T34	C0948089; Acute Coronary Syndrome; Disease or Syndrome
#90	AnnotatorNotes T78	C0948089; Acute Coronary Syndrome; Disease or Syndrome
#91	AnnotatorNotes T42	C2962754; P2Y12 Platelet Inhibitor; Pharmacologic Substance (?)
#92	AnnotatorNotes T50	C0040044; Thrombolytic Therapy; Therapeutic or Preventive Procedure
T90	Neg_cue 2390 2392	no
T92	Quantifier_or_Qualifier 2404 2413	incluidos
A16	Assertion T92 Negated
#93	AnnotatorNotes T92	C1512693; Inclusion; Qualitative Concept
T105	Neg_cue 1049 1052	sin
T106	Observation 1053 1078	elevación del segmento ST
A17	Assertion T106 Negated
#94	AnnotatorNotes T106	C0520886; ST segment elevation (finding); Finding
R1	Speculation Arg1:T104 Arg2:T17	
R2	Speculation Arg1:T104 Arg2:T66	
R3	Negation Arg1:T105 Arg2:T106	
R4	Negation Arg1:T90 Arg2:T92	
R5	Experiences Arg1:T81 Arg2:T1	
R6	Experiences Arg1:T81 Arg2:T2	
R7	Experiences Arg1:T81 Arg2:T5	
R8	Location_of Arg1:T59 Arg2:T5	
R9	Experiences Arg1:T82 Arg2:T9	
R10	Experiences Arg1:T82 Arg2:T10	
R11	Experiences Arg1:T82 Arg2:T13	
R12	Location_of Arg1:T60 Arg2:T13	
R15	Combined_with Arg1:T2 Arg2:T3	
R16	Combined_with Arg1:T2 Arg2:T4	
R19	Combined_with Arg1:T10 Arg2:T11	
R20	Combined_with Arg1:T10 Arg2:T12	
R21	Location_of Arg1:T61 Arg2:T14	
R22	Location_of Arg1:T62 Arg2:T15	
R23	Location_of Arg1:T62 Arg2:T8	
R24	Has_Age Arg1:T94 Arg2:T83	
R25	Overlap Arg1:T17 Arg2:T16	
R26	Location_of Arg1:T63 Arg2:T17	
R27	Location_of Arg1:T63 Arg2:T66	
T107	Quantifier_or_Qualifier 806 818	equivalentes
R28	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T107	
R29	Overlap Arg1:T18 Arg2:T16	
R31	Overlap Arg1:T16 Arg2:T84	
R32	Overlap Arg1:T19 Arg2:T84	
R30	Overlap Arg1:T18 Arg2:T66	
R33	Overlap Arg1:T66 Arg2:T16	
R34	After Arg1:T19 Arg2:T20	
R35	After Arg1:T16 Arg2:T20	
R36	Overlap Arg1:T63 Arg2:T26	
R37	Overlap Arg1:T26 Arg2:T21	
R38	Experiences Arg1:T94 Arg2:T16	
R39	Experiences Arg1:T94 Arg2:T17	
R40	Experiences Arg1:T94 Arg2:T66	
R41	Experiences Arg1:T94 Arg2:T18	
R42	Experiences Arg1:T94 Arg2:T19	
R43	Experiences Arg1:T94 Arg2:T20	
R44	Experiences Arg1:T94 Arg2:T26	
R45	Experiences Arg1:T94 Arg2:T21	
R46	Location_of Arg1:T64 Arg2:T23	
R47	Location_of Arg1:T64 Arg2:T24	
T108	Observation 985 1010	elevación del segmento ST
R48	Overlap Arg1:T25 Arg2:T106	
R49	Location_of Arg1:T65 Arg2:T25	
R50	Overlap Arg1:T23 Arg2:T108	
#95	AnnotatorNotes T108	C0520886; ST segment elevation (finding); Finding
R51	Overlap Arg1:T108 Arg2:T24	
R52	Location_of Arg1:T65 Arg2:T73	
R53	Overlap Arg1:T106 Arg2:T73	
R54	Has_Age Arg1:T95 Arg2:T86	
R55	Experiences Arg1:T95 Arg2:T27	
R56	Location_of Arg1:T67 Arg2:T28	
R57	Experiences Arg1:T95 Arg2:T28	
R58	Overlap Arg1:T28 Arg2:T29	
R59	Overlap Arg1:T27 Arg2:T29	
R60	Experiences Arg1:T95 Arg2:T29	
T109	CONC 1329 1349	periodo de selección
R61	Overlap Arg1:T79 Arg2:T109	
R62	After Arg1:T79 Arg2:T85	
R63	Experiences Arg1:T96 Arg2:T85	
R64	Overlap Arg1:T79 Arg2:T87	
R65	Has_Duration_or_Interval Arg1:T109 Arg2:T87	
R66	Experiences Arg1:T96 Arg2:T68	
R68	Experiences Arg1:T97 Arg2:T30	
R69	Used_for Arg1:T31 Arg2:T30	
R70	Used_for Arg1:T32 Arg2:T30	
R71	Has_Route_or_Mode Arg1:T32 Arg2:T88	
R72	Used_for Arg1:T70 Arg2:T33	
R73	Used_for Arg1:T70 Arg2:T72	
R74	Experiences Arg1:T97 Arg2:T33	
R75	Experiences Arg1:T97 Arg2:T72	
#96	AnnotatorNotes T72	C5197905; Dual Anti-Platelet Therapy; Therapeutic or Preventive Procedure 
#97	AnnotatorNotes T33	C5197905; Dual Anti-Platelet Therapy; Therapeutic or Preventive Procedure (?)
R76	Used_for Arg1:T35 Arg2:T72	
R77	Used_for Arg1:T35 Arg2:T33	
R78	Combined_with Arg1:T35 Arg2:T36	
R79	Combined_with Arg1:T37 Arg2:T38	
R80	Used_for Arg1:T37 Arg2:T33	
R81	Used_for Arg1:T37 Arg2:T72	
R82	Before Arg1:T33 Arg2:T39	
R83	Used_for Arg1:T71 Arg2:T39	
R84	Used_for Arg1:T42 Arg2:T39	
R85	After Arg1:T39 Arg2:T43	
R13	Before Arg1:T2 Arg2:T1	
R14	Before Arg1:T10 Arg2:T9	
R17	Used_for Arg1:T74 Arg2:T46	
T110	Observation 2191 2197	riesgo
R86	Experiences Arg1:T99 Arg2:T110	
R87	Experiences Arg1:T100 Arg2:T47	
R88	Experiences Arg1:T100 Arg2:T48	
R89	Has_Duration_or_Interval Arg1:T48 Arg2:T91	
R90	Has_Duration_or_Interval Arg1:T49 Arg2:T91	
R91	Experiences Arg1:T100 Arg2:T49	
R92	Used_for Arg1:T75 Arg2:T50	
A18	Status T75 History_of
R93	Experiences Arg1:T102 Arg2:T50	
R94	Experiences Arg1:T102 Arg2:T51	
R95	Experiences Arg1:T102 Arg2:T78	
R96	Has_Quantifier_or_Qualifier Arg1:T102 Arg2:T92	
A19	Assertion T52 Negated
R97	Negation Arg1:T90 Arg2:T52	
R98	Experiences Arg1:T102 Arg2:T52	
R100	Experiences Arg1:T101 Arg2:T76	
R101	Has_Duration_or_Interval Arg1:T53 Arg2:T93	
R99	Used_for Arg1:T53 Arg2:T76	
R102	Has_Duration_or_Interval Arg1:T54 Arg2:T93	
R103	Overlap Arg1:T53 Arg2:T56	
R104	Overlap Arg1:T54 Arg2:T56	
T111	Quantifier_or_Qualifier 2536 2548	concomitante
#98	AnnotatorNotes T111	C0521115; Simultaneous; Temporal Concept
R105	Has_Quantifier_or_Qualifier Arg1:T55 Arg2:T111	
R106	Has_Quantifier_or_Qualifier Arg1:T53 Arg2:T111	
R107	Has_Quantifier_or_Qualifier Arg1:T54 Arg2:T111	
R108	Experiences Arg1:T101 Arg2:T56	
R109	Experiences Arg1:T103 Arg2:T57	
R110	Experiences Arg1:T103 Arg2:T41	
R111	Causes Arg1:T58 Arg2:T57	
R112	Causes Arg1:T58 Arg2:T41	
R113	Causes Arg1:T77 Arg2:T57	
R114	Causes Arg1:T77 Arg2:T41	
T112	CONC 1477 1487	fase aguda
#99	AnnotatorNotes T112	C0439557; Acute phase; Temporal Concept
R115	Overlap Arg1:T30 Arg2:T112	
R116	Used_for Arg1:T54 Arg2:T76	
#100	AnnotatorNotes T110	C0559571; At risk; Finding
#101	AnnotatorNotes T107	C0205163; Equal; Qualitative Concept
R18	Experiences Arg1:T97 Arg2:T39	
A20	Experiencer T81 Patient
A21	Experiencer T82 Patient
A22	Experiencer T94 Patient
A23	Experiencer T95 Patient
A24	Experiencer T96 Patient
A25	Experiencer T97 Patient
A26	Experiencer T98 Patient
A27	Experiencer T99 Patient
A28	Experiencer T89 Other
A29	Experiencer T100 Patient
A30	Experiencer T102 Patient
A31	Experiencer T101 Patient
A32	Experiencer T103 Patient
